Oral News and Research

RSS

IOF presents eight young investigator awards to researchers across the world

Eight IOF Young Investigator Awards were presented by the International Osteoporosis Foundation (IOF) to young researchers from Australia, China, India and Japan, in recognition of their outstanding work. The awards, valued at 1,000 USD each, were awarded to the highest scored abstracts by researchers under the age of 40.

7 Sep 2011

SYSU, ASU collaborate to develop early and predictive diagnostics for colorectal cancer

Arizona State University (ASU) and China's Sun Yat-Sen University (SYSU) have formalized a research collaboration aimed at developing early and predictive diagnostics to improve patient outcomes for colorectal cancer.

7 Sep 2011

Robert Gordon University scientists to develop new treatment for cystinosis

A team of researchers at Robert Gordon University has secured a six figure sum from Sparks, a leading children’s medical research charity, to develop a revolutionary treatment for a rare genetic disorder.

6 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

Researchers discover how yeast cells identify, attach to human tissue and cause infection

Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.

6 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.

5 Sep 2011

Berlin to market wide range of Acino Pharma's current and future products in Thailand

Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma AG signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company's current and future products in Thailand.

5 Sep 2011

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.

3 Sep 2011

Simulation training helps students to score more on final examinations

Medical students who practiced on a patient simulator before assisting in real-life vaginal deliveries scored significantly higher on their final examinations than did students receiving a lecture only at the start of an obstetric clerkship.

3 Sep 2011

Key international experts to attend major European bone congress in Bourse, France

Key international experts in the bone field are to be featured speakers and session leaders at the upcoming European Congress on Osteoporosis & Osteoarthritis (IOF-ECCEO12). As the major European bone event of the year, IOF-ECCEO12 will present the latest research and clinical advances in the bone field.

3 Sep 2011

Sand fly's salivary components play a critical role in process for Leishmania

For millions of people who live under the constant threat of Leishmania infection, a new discovery by Brazilian scientists may lead to new breakthroughs, preventing these parasites from taking hold in the body or reducing the severity of infections once they occur.

2 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

HPV vaccination drives to prevent cervical cancers

Mexico plans to administer the vaccine against human papillomavirus (HPV), which can cause cervical cancer, to all girls beginning next year, the country's health ministry said Tuesday.

31 Aug 2011

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Aeterna Zentaris Inc. today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency.

31 Aug 2011

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

30 Aug 2011

AstraZeneca: BRILIQUE receives Class I recommendation from ESC

AstraZeneca today announced BRILIQUE, a new oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised "Guidelines for Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation."

30 Aug 2011

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

Oral News and Research

IOF presents eight young investigator awards to researchers across the world

SYSU, ASU collaborate to develop early and predictive diagnostics for colorectal cancer

Robert Gordon University scientists to develop new treatment for cystinosis

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

Researchers discover how yeast cells identify, attach to human tissue and cause infection

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Berlin to market wide range of Acino Pharma's current and future products in Thailand

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Simulation training helps students to score more on final examinations

Key international experts to attend major European bone congress in Bourse, France

Sand fly's salivary components play a critical role in process for Leishmania

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

HPV vaccination drives to prevent cervical cancers

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

AstraZeneca: BRILIQUE receives Class I recommendation from ESC

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News